Literature DB >> 34262038

Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses.

Zhijuan Yang1, Yujie Zhu1, Ziliang Dong1, Wei Li1, Nailin Yang1, Xianwen Wang1, Liangzhu Feng2, Zhuang Liu3,4.   

Abstract

Radiofrequency ablation (RFA) is clinically adopted to destruct solid tumors, but is often incapable of completely ablating large tumors and those with multiple metastatic sites. Here we develop a CaCO3-assisted double emulsion method to encapsulate lipoxidase and hemin with poly(lactic-co-glycolic acid) (PLGA) to enhance RFA. We show the HLCaP nanoreactors (NRs) with pH-dependent catalytic capacity can continuously produce cytotoxic lipid radicals via the lipid peroxidation chain reaction using cancer cell debris as the fuel. Upon being fixed inside the residual tumors post RFA, HLCaP NRs exhibit a suppression effect on residual tumors in mice and rabbits by triggering ferroptosis. Moreover, treatment with HLCaP NRs post RFA can prime antitumor immunity to effectively suppress the growth of both residual and metastatic tumors, also in combination with immune checkpoint blockade. This work highlights that tumor-debris-fueled nanoreactors can benefit RFA by inhibiting tumor recurrence and preventing tumor metastasis.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34262038     DOI: 10.1038/s41467-021-24604-9

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  32 in total

1.  Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors.

Authors:  Young-sun Kim; Hyo Keun Lim; Hyunchul Rhim; Min Woo Lee; Dongil Choi; Won Jae Lee; Seung Woon Paik; Kwang Cheol Koh; Joon Hyeok Lee; Moon Seok Choi; Geum-Youn Gwak; Byung Chul Yoo
Journal:  J Hepatol       Date:  2012-09-27       Impact factor: 25.083

Review 2.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

3.  Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.

Authors:  Rebecca Waitz; Stephen B Solomon; Elena N Petre; Anne E Trumble; Marcella Fassò; Larry Norton; James P Allison
Journal:  Cancer Res       Date:  2011-11-22       Impact factor: 12.701

4.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 5.  Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Loukia S Poulou; Evanthia Botsa; Ioanna Thanou; Panayiotis D Ziakas; Loukas Thanos
Journal:  World J Hepatol       Date:  2015-05-18

Review 6.  Image-guided ablation of primary liver and renal tumours.

Authors:  David J Breen; Riccardo Lencioni
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

7.  Amplification of Tumor Oxidative Stresses with Liposomal Fenton Catalyst and Glutathione Inhibitor for Enhanced Cancer Chemotherapy and Radiotherapy.

Authors:  Ziliang Dong; Liangzhu Feng; Yu Chao; Yu Hao; Muchao Chen; Fei Gong; Xiao Han; Rui Zhang; Liang Cheng; Zhuang Liu
Journal:  Nano Lett       Date:  2019-01-02       Impact factor: 11.189

8.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases.

Authors:  T de Baère; A Aupérin; F Deschamps; P Chevallier; Y Gaubert; V Boige; M Fonck; B Escudier; J Palussiére
Journal:  Ann Oncol       Date:  2015-02-16       Impact factor: 32.976

9.  Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode.

Authors:  Jae Won Choi; Jeong Min Lee; Dong Ho Lee; Jung Hwan Yoon; Yoon Jun Kim; Jeong Hoon Lee; Su Jong Yu; Eun Ju Cho
Journal:  Korean J Radiol       Date:  2020-07-22       Impact factor: 3.500

10.  Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells.

Authors:  Chen-Cheng Xue; Meng-Huan Li; Yang Zhao; Jun Zhou; Yan Hu; Kai-Yong Cai; Yanli Zhao; Shu-Hong Yu; Zhong Luo
Journal:  Sci Adv       Date:  2020-04-29       Impact factor: 14.957

View more
  6 in total

1.  Implantable Thermal Therapeutic Device with Precise Temperature Control Enabled by Foldable Electronics and Heat-Insulating Pads.

Authors:  Min Cai; Huang Yang; Liyin Shen; Shuang Nie; Zhengwei Mao; Changyou Gao; Yang Zhu; Jizhou Song
Journal:  Research (Wash D C)       Date:  2022-05-24

2.  Graphene Quantum Dots prepared by Electron Beam Irradiation for Safe Fluorescence Imaging of Tumor.

Authors:  Honghong Cao; Wei Qi; Xudong Gao; Qiang Wu; Longlong Tian; Wangsuo Wu
Journal:  Nanotheranostics       Date:  2022-01-01

Review 3.  Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential.

Authors:  Zachary J Senders; Robert C G Martin
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

4.  Metallo-alginate hydrogel can potentiate microwave tumor ablation for synergistic cancer treatment.

Authors:  Yujie Zhu; Zhijuan Yang; Zijian Pan; Yu Hao; Chunjie Wang; Ziliang Dong; Quguang Li; Yikai Han; Longlong Tian; Liangzhu Feng; Zhuang Liu
Journal:  Sci Adv       Date:  2022-08-03       Impact factor: 14.957

Review 5.  Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.

Authors:  Qin Xue; Jingliang Zhang; Jianhua Jiao; Weijun Qin; Xiaojian Yang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 6.  Rational Nanomedicine Design Enhances Clinically Physical Treatment-Inspired or Combined Immunotherapy.

Authors:  Qiaoqiao Liu; Wei Zhang; Rong Jiao; Zheng Lv; Xia Lin; Yunping Xiao; Kun Zhang
Journal:  Adv Sci (Weinh)       Date:  2022-08-24       Impact factor: 17.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.